Application of chimerism-based drug-induced tolerance to rat into mouse xenotransplantation

Scandinavian Journal of Immunology

Volumn 64, Issue 4, 2006, Pages 392-397

  Tomita, Y ^a   Shimizu, I ^a   Iwai, T ^a   Zhang, Q W ^a   Okano, S ^a   Kajiwara, T ^a   Onzuka, T ^a   Tominaga, R ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL POPULATION; CHIMERA; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; MOUSE; NATURAL KILLER CELL; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; RAT; SKIN GRAFT; SPLEEN CELL; T LYMPHOCYTE; XENOTRANSPLANTATION;

ANIMALS; BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; GRAFT ENHANCEMENT, IMMUNOLOGIC; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; RATS; RATS, INBRED F344; RATS, INBRED LEW; SKIN TRANSPLANTATION; SPLEEN; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HETEROLOGOUS;

EID: 33748806800     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2006.01831.x     Document Type: Article

References (33)

1. Shin T, Mayumi H, Himeno K, Sanui H, Nomoto K. Drug-induced tolerance to allografts in mice. I. Difference between tumor and skin grafts. Transplantation 1984;37:580-4.
2. Mayumi H, Shin T, Himeno K, Nomoto K. Drug-induced tolerance to allografts in mice. II. Tolerance to tumor allografts of large doses associated with rejection of skin allografts and tumor allografts of small doses. Immunobiology 1985;169:147-61.
3. Tomita Y, Yoshikawa M, Zhang QW et al. Induction of permanent mixed chimerism and skin allograft tolerance across fully MHC-mismatched barriers by the additional myelosuppressive treatments in mice primed with allogeneic spleen cells followed by cyclophosphamide. J Immunol 2000;165:34-41.
4. Sykes M, Sachs DH. Mixed allogeneic chimerism as an approach to transplantation tolerance. Immunol Today 1988;9:23-7.
5. Mayumi H, Himeno K, Shin T, Nomoto K. Drug-induced tolerance to allografts in mice. IV. Mechanisms and kinetics of cyclophosphamide-induced tolerance. Transplantation 1985;39:209-15.
6. Mayumi H, Himeno K, Tanaka K, Tokuda N, Fan JL, Nomoto K. Drug-induced tolerance to allografts in mice. XII. The relationships between tolerance, chimerism, and graft-versus-host disease. Transplantation 1987;44:286-90.
7. Tomita Y, Mayumi H, Eto M, Nomoto K. Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance? J Immunol 1990;144:463-73.
8. Eto M, Mayumi H, Tomita Y, Yoshikai Y, Nomoto K. Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens. J Exp Med 1990;171:97-113.
9. Tomita Y, Nishimura Y, Harada N et al. Evidence for involvement of clonal anergy in MHC class I and class II disparate skin allograft tolerance after the termination of intrathymic clonal deletion. J Immunol 1990;145:4026-36.
10. Eto M, Mayumi H, Tomita Y, Yoshikai Y, Nishimura Y, Nomoto K. Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion. J Immunol 1990;145:1303-10.
11. Zhang QW, Mayumi H, Umesue M, Tomita Y, Nomoto K, Yasui H. Fractionated dosing of cyclophosphamide for establishing long-lasting skin allograft survival, stable mixed chimerism, and intrathymic clonal deletion in mice primed with allogeneic spleen cells. Transplantation 1997;63:1667-73.
12. Maeda T, Eto M, Nishimura Y, Nomoto K, Kong YY, Nomoto K. Role of peripheral hemopoietic chimerism in achieving donor-specific tolerance in adult mice. J Immunol 1993;150:753-62.
13. Yoshikawa M, Tomita Y, Uchida T, Zhang QW, Nomoto K. Lack of pluripotent stem cell engraftment in cyclophosphamide-induced tolerance. Transplant Proc 1999;31:898-9.
14. Yoshikawa M, Tomita Y, Uchida T, Zhang QW, Shimizu I, Nomoto K. Cyclophosphamide 200 mg/kg lacks ability to induce pluripotent stem cell engraftment in mice. Transplant Proc 1999;31:1939.
15. Shimizu I, Tomita Y, Iwai T et al. Efficacy and limitations of cyclophosphamide-induced tolerance against alphaGal antigen. Scand J Immunol 2005;62:271-80.
16. Shimizu I, Smith NR, Zhao G, Medof E, Sykes M. Decay-accelerating factor prevents acute humoral rejection induced by low levels of anti-alphaGal natural antibodies. Transplantation 2006;81:95-100.
17. Sandrin MS, Vaughan HA, Dabkowski PL, McKenzie IF. Anti-pig IgM antibodies in human serum react predominantly with Gal(alpha 1-3)Gal epitopes. Proc Natl Acad Sci U S A 1993;90:11391-5.
18. Kuwaki K, Tseng YL, Dor FJ et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 2005;11:29-31.
19. Yamada K, Yazawa K, Shimizu A et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 2005;11:32-4.
20. Adams DH, Kadner A, Chen RH, Farivar RS. Human membrane cofactor protein (MCP, CD 46) protects transgenic pig hearts from hyperacute rejection in primates. Xenotransplantation 2001;8:36-40.
21. Wen L, Shinton SA, Hardy RR, Hayakawa K. Association of B-1 B cells with follicular dendritic cells in spleen. J Immunol 2005;174:6918-26.
22. Ohdan H, Swenson KG, Kruger Gray HS et al. Mac-1-negative B-1b phenotype of natural antibody-producing cells, including those responding to Gal alpha 1,3 Gal epitopes in alpha 1,3-galactosyltransferase-deficient mice. J Immunol 2000;165:5518-29.
23. Viau M, Zouali M. B-lymphocytes, innate immunity, and autoimmunity. Clin Immunol 2005;114:17-26.
24. Ohdan H, Yang YG, Shimizu A, Swenson KG, Sykes M. Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal alpha 1,3 Gal-mediated graft rejection. J Clin Invest 1999;104:281-90.
25. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984;307:168-70.
26. Ildstad ST, Wren SM, Boggs SS, Hronakes ML, Vecchini F, Van den Brink MR. Cross-species bone marrow transplantation: evidence for tolerance induction, stem cell engraftment, and maturation of T lymphocytes in a xenogeneic stromal environment (rat-mouse). J Exp Med 1991;174:467-78.
27. Yokoyama WM, Kim S. How do natural killer cells find self to achieve tolerance? Immunity 2006;24:249-57.
28. Johansson S, Johansson M, Rosmaraki E et al. Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. J Exp Med 2005;201:1145-55.
29. Kitchens WH, Uehara S, Chase CM, Colvin RB, Russell PS, Madsen JC. The changing role of natural killer cells in solid organ rejection and tolerance. Transplantation 2006;81:811-7.
30. Raziuddin A, Longo DL, Bennett M, Winkler-Pickett R, Ortaldo JR, Murphy WJ. Increased bone marrow allograft rejection by depletion of NK cells expressing inhibitory Ly49 NK receptors for donor class I antigens. Blood 2002;100:3026-33.
31. Liu J, Morris MA, Nguyen P et al. Ly49I NK cell receptor transgene inhibition of rejection of H2b mouse bone marrow transplants. J Immunol 2000;164:1793-9.
32. Adams AB, Durham MM, Kean L et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 2001;167:1103-11.
33. Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995;1:1268-73.